Embecta (Nasdaq:EMBC) announced today that it held a grand opening ceremony at its new global headquarters in New Jersey.
The BD Diabetes business spinoff opened its new headquarters at 300 Kimball Drive, Suite 300, in Parsippany, New Jersey. The site houses members of the Embecta leadership team, global support functions and North American commercial organization.
Embecta has approximately 2,000 employees globally.
“With a number of our employees currently making their homes in New Jersey, the ability to tap into one of the nation’s most significant concentrations of highly-educated, experienced medical technology talent, and easy access to international airports and interstate highways, we see Parsippany as the ideal location to establish our worldwide headquarters,” said Devdatt (Dev) Kurdikar, president and CEO, Embecta. “We are a new company, but our roots in New Jersey go back nearly 100 years when, as part of BD, we developed the first dedicated insulin syringe in 1924. We’re looking forward to advancing that legacy as we continue to develop and provide solutions that make life better for people living with diabetes.”
More about the new Embecta HQ
The 55,600-square-foot office suite offers employees both tools and flexibility to collaborate. It offers in-person and global collaboration opportunities with Embecta’s geographically dispersed teams. The business covers customers in more than 100 countries.
It features ample open workspace, spaces for video conferencing, huddle rooms and reservable private spaces. The Embecta headquarters also includes a showroom for product demonstrations and on-site customer meetings.
Embecta selected CBRE as its partner in choosing, designing and building out the office.
“We’re pleased that Embecta has chosen to make a long-term commitment to New Jersey, adding to the roster of life sciences and medical technology companies that make the core of the Garden State’s innovation economy,” said Governor Phil Murphy. “Diabetes is one of the world’s most pressing health care issues, with an enormous cost burden and a societal impact that extends to friends, loved ones and caregivers. Embecta’s vision of a life unlimited by diabetes is closely aligned with our own efforts to invest in, and expand, the state’s public health infrastructure.”
What does 2023 hold?
With a new headquarters, Embecta started the year off with a bang. Many eyes will remain on the company for more details about its new diabetes technology product under development.
Embecta is developing a patch pump technology for insulin delivery, but details remain sparse.
Analysts were hopeful to learn more at the end of the year about the company’s insulin patch pump, but so far Embecta has been tight-lipped. More updates may come this year.
